本文選題：肌層浸潤性膀胱癌 + 經(jīng)尿道膀胱腫瘤電切術(shù)��； 參考：《吉林大學(xué)》2014年碩士論文

【摘要】：目的：探討表柔比星與羥喜樹堿膀胱灌注在預(yù)防肌層浸潤性胱癌行經(jīng)尿道膀胱腫瘤電切術(shù)后復(fù)發(fā)的臨床療效及安全性。 方法：選取行經(jīng)尿道膀胱腫瘤電切術(shù)（TUR-BT）的膀胱癌患者，根據(jù)術(shù)后病理與患者及患者家屬的意愿選擇符合要求的43例肌層浸潤性膀胱癌患者，將43例患者隨機(jī)分成兩組，A組23例患者（表柔比星組），B組20例患者（羥喜樹堿組），術(shù)后24小時(shí)內(nèi)行表柔比星50mg（或者羥喜樹堿40mg）+生理鹽水20ml膀胱灌注化療，1h后開放尿管，術(shù)后1周起采用原劑量行膀胱內(nèi)灌注化療。表柔比星灌注方案為1次/周，連續(xù)8周，然后1次/月×10次，共1年，羥喜樹堿灌注化療方案為1次/周，連續(xù)8周，然后1次/2周×8次，再行1次/月×18次，共2年。隨訪比較兩組患者術(shù)后腫瘤復(fù)發(fā)及發(fā)生并發(fā)癥情況。 結(jié)果：43例患者的治療隨訪時(shí)間為13—44個(gè)月，肌層浸潤性膀胱腫瘤患者應(yīng)用表柔比星與羥喜樹堿在比較1年內(nèi)復(fù)發(fā)率各為13.0%，20.0%，2年內(nèi)復(fù)發(fā)率各為34.8%，30.0%，均無統(tǒng)計(jì)學(xué)差異（P＞0.05），兩者在預(yù)防膀胱腫瘤復(fù)發(fā)中均無明顯的優(yōu)越性。 結(jié)論：肌層浸潤性膀胱癌患者行經(jīng)尿道膀胱腫瘤電切術(shù)后并長期規(guī)律膀胱灌注表柔比星或羥喜樹堿治療達(dá)到了較為滿意的療效，膀胱內(nèi)灌表柔比星和羥喜樹堿化療藥物安全性與臨床耐受性良好，患者手術(shù)指征掌握恰當(dāng)，并且術(shù)后注意密切隨訪與復(fù)查，可顯著提高患者術(shù)后的生活質(zhì)量。
[Abstract]:Objective: to investigate the clinical efficacy and safety of epirubicin and hydroxycamptothecin in preventing recurrence of myometrial invasive cystoma after transurethral resection of bladder tumor.Methods: patients with bladder cancer underwent transurethral resection of bladder tumor (TUR-BT). According to the postoperative pathology and the wishes of the patients and their families, 43 patients with myometrial invasive bladder cancer were selected.43 patients were randomly divided into two groups: group A (n = 23) (epirubicin group, n = 20), group B (n = 20) (hydroxycamptothecin group, n = 20). Within 24 hours after operation, 30 mg of epirubicin (or 40 mg of hydroxycamptothecin) were given intravesical infusion chemotherapy of epirubicin (50 mg) or hydroxycamptothecin (40 mg).Intravesical infusion chemotherapy was performed 1 week after operation.Epirubicin was given once a week for 8 weeks, then once a month 脳 10 times for a total of 1 year. Hydrocamptothecin infusion regimen was given once a week for 8 weeks, then 1 / 2 weeks 脳 8 times, and 1 / month 脳 18 times for 2 years.Tumor recurrence and complications were compared between the two groups.Results 43 patients were followed up for 13-44 months.The recurrence rates of epirubicin and hydroxycamptothecin in patients with intramuscular invasive bladder tumor were 13.0% 20.0 in 1 year and 30.0% in 2 years, respectively. There was no significant difference between them (P > 0.05). There was no obvious superiority in preventing the recurrence of bladder tumor between the two groups.Conclusion: after transurethral resection of bladder neoplasms and long-term regular bladder instillation of epirubicin or hydroxycamptothecin in patients with myometrial invasive bladder cancer, satisfactory results have been achieved.The safety and clinical tolerance of intravesical instillation of epirubicin and hydroxycamptothecin were good.
【學(xué)位授予單位】：吉林大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2014
【分類號】：R737.14

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 王春榮;林宗明;;膀胱腫瘤標(biāo)記物的研究進(jìn)展[J];國際泌尿系統(tǒng)雜志;2006年01期

2 王章才;全膀胱切除術(shù)治療膀胱癌手術(shù)時(shí)機(jī)的探討[J];臨床泌尿外科雜志;2000年06期

3 柳建軍,曹軍,蘇勁,李普云;P53、C-erbB-2和bcl-2基因在膀胱癌中的表達(dá)及意義[J];臨床泌尿外科雜志;2001年08期

4 李和程,石濤,王子明;P53和MDM2基因表達(dá)及與膀胱癌生物學(xué)行為的關(guān)系[J];臨床泌尿外科雜志;2001年12期

5 侯建國,楊波,孫穎浩,萬蓬;浸潤性膀胱癌患者的保留膀胱綜合治療[J];臨床泌尿外科雜志;2004年10期

6 周四維，楊為民，葉章群，，趙建軍;卡介苗膀胱灌注的并發(fā)癥及其防治（附9例報(bào)告）[J];臨床泌尿外科雜志;1996年01期

7 湯海;唐涌志;陳向東;丁滿棠;張文鼎;肖軍;;膀胱內(nèi)不同化療藥物灌注預(yù)防淺表型膀胱腫瘤復(fù)發(fā)的臨床觀察[J];現(xiàn)代泌尿外科雜志;2008年01期

8 崔軍;宋永勝;郭啟振;;欖香烯與表柔比星預(yù)防低級別淺表性膀胱尿路上皮癌術(shù)后復(fù)發(fā)[J];實(shí)用藥物與臨床;2012年11期

9 姚海軍;應(yīng)俊;任曉敏;姚德鴻;;高危膀胱癌膀胱部分切除術(shù)后法瑪新膀胱灌注化療的療效觀察[J];中國全科醫(yī)學(xué);2008年22期

10 何杰,汪萬英,朱應(yīng)葆,姚敏;p16和bcl-2基因在膀胱癌中的表達(dá)及意義[J];腫瘤學(xué)雜志;2001年02期

本文編號：1756559